DrugPatentWatch Database Preview
Hoffmann La Roche Company Profile
Email this page to a colleague
» See Plans and PricingWhat is the competitive landscape for HOFFMANN LA ROCHE, and when can generic versions of HOFFMANN LA ROCHE drugs launch?
HOFFMANN LA ROCHE has thirteen approved drugs.
There are twelve US patents protecting HOFFMANN LA ROCHE drugs.
There are three hundred and seven patent family members on HOFFMANN LA ROCHE drugs in fifty-two countries and twenty-nine supplementary protection certificates in sixteen countries.
Summary for Hoffmann La Roche
| International Patents: | 307 |
| US Patents: | 12 |
| Tradenames: | 11 |
| Ingredients: | 10 |
| NDAs: | 13 |
Drugs and US Patents for Hoffmann La Roche
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hoffmann La Roche | ROCEPHIN KIT | ceftriaxone sodium; lidocaine | INJECTABLE;INJECTION | 050585-007 | May 8, 1996 | DISCN | No | No | Start Trial | Start Trial | |||||
| Hoffmann La Roche | ROCEPHIN | ceftriaxone sodium | INJECTABLE;INJECTION | 062654-003 | Apr 30, 1987 | DISCN | No | No | Start Trial | Start Trial | |||||
| Hoffmann La Roche | ACCUTANE | isotretinoin | CAPSULE;ORAL | 018662-003 | May 7, 1982 | DISCN | Yes | No | Start Trial | Start Trial | |||||
| Hoffmann La Roche | ROCEPHIN | ceftriaxone sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 050585-002 | Dec 21, 1984 | DISCN | Yes | No | Start Trial | Start Trial | |||||
| Hoffmann La Roche | ROCEPHIN | ceftriaxone sodium | INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | 050585-001 | Dec 21, 1984 | DISCN | Yes | No | Start Trial | Start Trial | |||||
| Hoffmann La Roche | ZELBORAF | vemurafenib | TABLET;ORAL | 202429-001 | Aug 17, 2011 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Hoffmann La Roche | VALCYTE | valganciclovir hydrochloride | TABLET;ORAL | 021304-001 | Mar 29, 2001 | AB | RX | Yes | Yes | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Hoffmann La Roche
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Hoffmann La Roche | XELODA | capecitabine | TABLET;ORAL | 020896-001 | Apr 30, 1998 | 5,472,949*PED | Start Trial |
| Hoffmann La Roche | FORTOVASE | saquinavir | CAPSULE;ORAL | 020828-001 | Nov 7, 1997 | 5,196,438*PED | Start Trial |
| Hoffmann La Roche | ACCUTANE | isotretinoin | CAPSULE;ORAL | 018662-002 | May 7, 1982 | 4,464,394*PED | Start Trial |
| Hoffmann La Roche | ACCUTANE | isotretinoin | CAPSULE;ORAL | 018662-002 | May 7, 1982 | 4,200,647 | Start Trial |
| Hoffmann La Roche | ACCUTANE | isotretinoin | CAPSULE;ORAL | 018662-003 | May 7, 1982 | 4,464,394*PED | Start Trial |
| Hoffmann La Roche | BONIVA | ibandronate sodium | TABLET;ORAL | 021455-001 | May 16, 2003 | 4,927,814 | Start Trial |
| Hoffmann La Roche | ACCUTANE | isotretinoin | CAPSULE;ORAL | 018662-004 | Mar 28, 1983 | 4,335,125 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for HOFFMANN LA ROCHE drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 450 mg | ➤ Subscribe | 2005-12-27 |
| ➤ Subscribe | Injection | 1 mg/mL, 3 mL Vial | ➤ Subscribe | 2007-08-31 |
| ➤ Subscribe | Tablets | 150 mg and 500 mg | ➤ Subscribe | 2008-11-10 |
| ➤ Subscribe | For Oral Solution | 50 mg/mL | ➤ Subscribe | 2011-03-21 |
| ➤ Subscribe | Tablets | 2.5 mg and 150 mg | ➤ Subscribe | 2007-05-16 |
Premature patent expirations for HOFFMANN LA ROCHE
Expiration due to failure to pay maintenance fee
| Patent Number | Expiration Date |
|---|---|
| Start Trial | Start Trial |
International Patents for Hoffmann La Roche Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Malaysia | 160737 | Start Trial |
| China | 102361870 | Start Trial |
| European Patent Office | 2414356 | Start Trial |
| China | 102574799 | Start Trial |
| South Africa | 200407950 | Start Trial |
| Denmark | 1131037 | Start Trial |
| Slovenia | 1696920 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Hoffmann La Roche Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1893612 | 2012/025 | Ireland | Start Trial | PRODUCT NAME: VEMURAFENIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/12/751/001 20120217 |
| 1893612 | 12C0040 | France | Start Trial | PRODUCT NAME: VEMURAFENIB, EVENTUELLEMENT SOUS LA FORME D'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/12/751/001 20120217 |
| 0316704 | SPC/GB01/015 | United Kingdom | Start Trial | PRODUCT NAME: CAPECITABINE AND HYDRATES AND SOLVATES THEREOF; REGISTERED: CH 54657 19980610; UK EU/1/00/163/001-002 20010202 |
| 1893612 | 122012000043 | Germany | Start Trial | PRODUCT NAME: VEMURAFENIB ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/12/751/001 20120217 |
| 1893612 | 462 | Finland | Start Trial | |
| 1893612 | C300534 | Netherlands | Start Trial | PRODUCT NAME: VEMURAFENIB ALSMEDE FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/12/751/001 20120217 |
| 0432695 | 32/1996 | Austria | Start Trial | PRODUCT NAME: SAQUINAVIR UND SEINE SAEUREADDITIONSSALZE, INSBESONDERE SAQUINAVIRMESYLAT; REGISTRATION NO/DATE: EU/1/96/026/001 19961004 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
